Publications

Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access certain medications for infantile onset lysosomal acid lipase deficiency (LAL-D) under the Life Saving Drugs Program.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Infantile-onset lysosomal acid-lipase deficiency disease (LAD-D).

Treating Physicians use this application form to apply for a patient to access LSDP medication for Infantile-onset lysosomal acid-lipase deficiency disease (LAD-D) for the first time, or after a break.

These guidelines contain the general, initial and ongoing eligibility requirements to access certain medications for Gaucher disease (type 1) under the Life Saving Drugs Program.

Treating physicians use this application form to apply for a patient to access LSDP medication for Gaucher disease for the first time, or after a break.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Gaucher disease.

Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.

Arrangements for image-based prescribing implemented at the start of the COVID-19 pandemic will cease on 31 March 2023 in all settings. Electronic prescribing is now widely available in Australia and provides an option for supporting telehealth consultations and enabling supply of medicines.

Electronic prescribing was fast-tracked as part of the National Health Plan for coronavirus (COVID-19). This guide for pharmacists outlines arrangements available that will help patients receive medicines via telehealth services.

Electronic prescribing has been fast-tracked as part of the National Health Plan for coronavirus (COVID-19). This guide for prescribers outlines the temporary arrangements available now that will help patients receive medicines via telehealth services.

This fridge magnet card outlines the series of recommended vaccines available free for children aged 0 to 4 years under the National Immunisation Program.

This campaign poster encourages you to vaccinate your child.

This brochure provides information about the recommended vaccines available free for children under the National Immunisation Program.

This COVID-19 top up poster contains promotional information about booking your free booster.

This COVID-19 top up poster contains promotional information about booking your free booster.

This communique summarises the meeting of the Culturally and Linguistically Diverse (CALD) Communities COVID-19 Health Advisory Group (Advisory Group), held on 22 March 2023.

This weekly report provides a snapshot of data on the impact of COVID-19 in residential aged care facilities nationally. The report includes data on the number of services impacted and number of staff and resident cases, as well as workforce, testing and PPE provided to affected services.

This fact sheet outlines the changes to the Pharmaceutical Benefits Scheme (PBS) for pharmacists and medical practitioners.

VCF Connect allows vaccination providers to self-manage vaccination service information.

This infographic issued on 31 March 2023 provides a weekly traffic light report of the coronavirus (COVID-19) situation across Australia.

This fact sheet provides information about biosimilar brands of trastuzumab listed on the Pharmaceutical Benefits Scheme (PBS).

This fact sheet provides information about biosimilar brands of bevacizumab listed on the Pharmaceutical Benefits Scheme (PBS).

This document contains answers to questions about the exemption framework for the 24/7 registered nurse (RN) responsibility, including questions and answers received prior to and during the webinar hosted by the Department of Health and Aged Care (the department) on 15 March 2023.

This report, and accompanying table, provide a fortnightly summary on notifications of Australia's nationally notifiable diseases for 06 March 2023 to 19 March 2023